Losing weight with anti-obesity medications (AOM) also resulted in decreased alcohol consumption for about half of the participants in a new study appearing in the current issue of JAMA Network Open .

To help the NHS manage demand, the health organisation's spending watchdog said about 220,000 people could benefit from the ...

After this, the situation will be reviewed by Nice, who will provide further guidance on the rollout. Mounjaro is a ...

After this, the situation will be reviewed by Nice, who will provide further guidance on the rollout. Mounjaro is a ...

Amid the war on obesity, a clear winner has emerged in a battle between two weight-loss injectables. Zepbound (tirzepatide), ...

Speaking at The New York Times’s DealBook Summit, Eli Lilly’s chief executive and an obesity medicine specialist discussed ...

The table below is a review of notable updates that occurred in November 2024 for investigational products in development (not an inclusive list). Click on the status to view our full coverage. The ...

Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data.

Patients lost an average of 20.2% of their weight with tirzepatide over 72 weeks versus 13.7% with semaglutide.

GLP-1RA medications in preadolescents and adolescents were concentrated among those with diabetes, obesity, mood disorders, and anxiety.

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use may reduce alcohol consumption and improve outcomes in some individuals.